277 - Comparative Safety Profile of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy for Inflammatory Bowel Disease: A Multicenter Consortium Propensity Score-Matched Analysis
暂无分享，去创建一个
Siddharth Singh | B. Sands | C. Siegel | W. Sandborn | E. Loftus | D. Faleck | P. Dulai | B. Boland | J. Colombel | Shannon Chang | A. Swaminath | G. Kochhar | S. Kane | D. Hudesman | D. Lukin | B. Shen | R. Hirten | M. Fischer | J. Koliani-Pace | E. Shmidt | J. Meserve | A. Winters | M. Bohm | S. Aniwan | N. Gupta | A. Weiss | Siri R Kadire | M. Rahal | P. Shashi | G. Tran | Shreya Chablaney | Sashivar Sagi | S. Keith